https://www.selleckchem.com/pr....oducts/pf-04957325.h
The actuarial initial remission was 44% at two years, 67% at four years, and 89% at six years. The mean recurrence-free survival was 128 months. Age and pre-GKRS morning serum cortisol were found to be predictors for initial and durable endocrine remissions. New-onset hypopituitarism was observed in two of five patients (40%). None of the patients developed new neurological deficits and had GKRS-related adverse events during the follow-up. Whole-sellar GKRS is a safe and efficient method to manage MRInegative CD and provides similar
Respect!
Kommentar
Delen
